| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia
|
Montesinos, Pau
|
|
|
91 |
5 |
p. 441-446
|
artikel
|
| 2 |
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial
|
Puszkiel, Alicja
|
|
|
91 |
5 |
p. 413-425
|
artikel
|
| 3 |
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity
|
Tambe, Prasad Kisan
|
|
|
91 |
5 |
p. 389-400
|
artikel
|
| 4 |
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
|
Varnier, Romain
|
|
|
91 |
5 |
p. 361-373
|
artikel
|
| 5 |
Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer
|
Nihei, Satoru
|
|
|
91 |
5 |
p. 427-434
|
artikel
|
| 6 |
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report
|
Baiardi, Giammarco
|
|
|
91 |
5 |
p. 435-439
|
artikel
|
| 7 |
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer
|
Muj, Chukhu
|
|
|
91 |
5 |
p. 375-387
|
artikel
|
| 8 |
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent
|
Bré, Jennifer
|
|
|
91 |
5 |
p. 401-412
|
artikel
|
Tijdschrift beschrijving